In the RAS/BRAF‐wt subset, 1.3% were MSI‐H and 4.1% TMB‐H, whereas in the RAS/BRAF‐altered subset 2.0% were MSI‐H and 5.0% TMB‐H in rectal cancer (P < 0.05, Fisher's exact test, Figs S3D, S4D). This evidence concerns the gene BRAF and rectal cancer.